Potential Synergy

by Hope G. Casto, Alexandra Steinhauer, Pamela M. Pollock
Published 2013-11-01

Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer

by Asmerom T. Sengal, Deborah Smith, Rebecca Rogers, Cameron E. Snell, Elizabeth D. Williams, Pamela M. Pollock
Published 2021-04-01

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

by Sara A. Byron, Michael Gartside, Matthew A. Powell, Candice L. Wellens, Feng Gao, David G. Mutch, Paul J. Goodfellow, Pamela M. Pollock
Published 2012-01-01

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

by Sara A Byron, Michael Gartside, Matthew A Powell, Candice L Wellens, Feng Gao, David G Mutch, Paul J Goodfellow, Pamela M Pollock
Published 2012-01-01

Correction: Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, , , Mutations and Clinicopathological Features.

by Sara A. Byron, Michael Gartside, Matthew A. Powell, Candice L. Wellens, Feng Gao, David G. Mutch, Paul J. Goodfellow, Pamela M. Pollock
Published 2012-01-01

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

by Sara A Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G Gartside, Farhad Dehkhoda, Steven P Blais, Thomas A Neubert, Moosa Mohammadi, Pamela M Pollock
Published 2013-08-01

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

by Leisl M. Packer, Samantha J. Stehbens, Vanessa F. Bonazzi, Jennifer H. Gunter, Robert J. Ju, Micheal Ward, Michael G. Gartside, Sara A. Byron, Pamela M. Pollock
Published 2019-04-01

Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen

by Sugandha Bhatia, Tony Blick, Cletus Pinto, Mark Waltham, James Monkman, Ekaterina Ivanova, Pamela M. Pollock, Shivashankar H. Nagaraj, Adrian P. Wiegmans, Izhak Haviv, Kaylene J. Simpson, Erik W. Thompson
Published 2020-04-01

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitio...

by Florine A. Eggink, Inge C. Van Gool, Alexandra Leary, Pamela M. Pollock, Emma J. Crosbie, Linda Mileshkin, Ekaterina S. Jordanova, Julien Adam, Luke Freeman-Mills, David N. Church, Carien L. Creutzberg, Marco De Bruyn, Hans W. Nijman, Tjalling Bosse
Published 2017-02-01

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

by Mitchell S. Stark, Kerenaftali Klein, Benjamin Weide, Lauren E. Haydu, Annette Pflugfelder, Yue Hang Tang, Jane M. Palmer, David C. Whiteman, Richard A. Scolyer, Graham J. Mann, John F. Thompson, Georgina V. Long, Andrew P. Barbour, H. Peter Soyer, Claus Garbe, Adrian Herington, Pamela M. Pollock, Nicholas K. Hayward
Published 2015-07-01

A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells

by Jacqui A. McGovern, Nathalie Bock, Abbas Shafiee, Laure C. Martine, Ferdinand Wagner, Jeremy G. Baldwin, Marietta Landgraf, Christoph A. Lahr, Christoph Meinert, Elizabeth D. Williams, Pamela M. Pollock, Jim Denham, Pamela J. Russell, Gail P. Risbridger, Judith A. Clements, Daniela Loessner, Boris M. Holzapfel, Dietmar W. Hutmacher
Published 2021-08-01